

ERRATUM

Erratum for the Clinical and Translational Medicine 'LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability' by Yiran Zhu et al.

Yiran Zhu¹  | Bingluo Zhou¹ | Xinyang Hu¹ | Shilong Ying¹ | Qiyin Zhou² |
Wenxia Xu¹ | Lifeng Feng¹  | Tianlun Hou³ | Xian Wang² | Liyuan Zhu¹ |
Hongchuan Jin¹

¹Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

²Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

³Department of Clinical Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China

Correspondence

Dr. Liyuan Zhu, and Dr. Hongchuan Jin, Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Email: 0016644@zju.edu.cn and jinhc@zju.edu.cn

Funding information

National Natural Science Foundation of China, Grant/Award Numbers: 81903061, 91740106

Following the publication of the original article,¹ the authors identified a minor error in Figure 1G, where the western blot image of the α -tubulin reference for SGC-R was inadvertently duplicated with that of BGC-R. We sincerely apologise for any confusion this may have caused. It is important to note that this error did not affect the overall results, as the cleavage of PARP1 and caspase-3 was appropriately supported by the levels of total PARP1 and caspase-3.

(G)




FIGURE 1 Original Figure 1 (G) with red block: Apoptotic cells among LNC942 knocked-down SGC-R and BGC-R cells were treated with DDP (8 μ g/ml) for 24 h and then analysed by anti-cleaved-PARP1 and cleaved-caspase 3 through western blotting.

This is an open access article under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *Clinical and Translational Medicine* published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

(G)




FIGURE 1 Updated Figure 1 (G): Apoptotic cells among LNC942 knocked-down SGC-R and BGC-R cells were treated with DDP (8 μ g/ml) for 24 h and then analysed by anti-cleaved-PARP1 and cleaved-caspase 3 through western blotting.

We have located the original western blot data for the α -tubulin reference for SGC-R and have made the necessary corrections to Figure 1G. Importantly, we assure readers that this erratum does not impact the conclusions or descriptions presented in the article.

1. Zhu, Y., Zhou, B., Hu, X., Ying, S., Zhou, Q., Xu, W., Feng, L., Hou, T., Wang, X., Zhu, L., & Jin, H. (2022, Jan). LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. *Clin Transl Med*, 12(1), e703. <https://doi.org/10.1002/ctm2.703>

ORCID

Yiran Zhu  <https://orcid.org/0000-0002-5761-8915>

Lifeng Feng  <https://orcid.org/0000-0003-4506-1213>